[poinsettia: notice of Application for Supplementary Application for Levocetirizine Hydrochloride Oral Drops] FAP, June 13, poinsettia announcement, poinsettia Pharmaceuticals, a wholly owned subsidiary, received a notice of approval for supplemental application for levocetirizine hydrochloride oral drops. Levocetirizine, as the third generation antihistamine, has dual anti-allergic effects of antihistamine and anti-inflammation.